Related Experiment Video

Updated: Jul 20, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia]

Anna Soler1, Elisabet Deig, Josep Guil

  • 1Unitat de Malalties Infeccioses-VIH, Fundació Hospital-Asil de Granollers, Granollers, Barcelona, Spain.

Medicina Clinica
|September 1, 2006
PubMed

Insights

Atorvastatin effectively treated hypercholesterolemia in HIV patients on antiretroviral therapy. The drug demonstrated good tolerance and safety, with a high success rate in achieving therapeutic goals.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Hypercholesterolemia is a common complication in patients with Human Immunodeficiency Virus (HIV) undergoing antiretroviral treatment.
  • Secondary dyslipidemia in HIV patients requires effective and safe management strategies.

Purpose of the Study:

  • To evaluate the effectiveness and tolerance of atorvastatin in managing hypercholesterolemia in HIV-positive patients.
  • To assess the safety profile of atorvastatin in this specific patient population.

Main Methods:

  • A prospective study involving HIV+ patients with secondary dyslipidemia meeting NCEP-III criteria.
  • Patients received 10 mg/day of atorvastatin, with a potential dose increase to 20 mg/day.
  • Follow-up duration was 6 months.

Main Results:

  • The study included 32 patients.
  • Therapeutic objectives were achieved in 62% of cases.
  • Atorvastatin demonstrated good clinical tolerance, with only one adverse event requiring drug discontinuation.

Conclusions:

  • Atorvastatin is an effective treatment for dyslipidemia in HIV patients.
  • Atorvastatin is safe and well-tolerated in this population.
  • The findings support the use of atorvastatin for managing hypercholesterolemia in HIV-infected individuals on antiretroviral therapy.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Bioavailability: Influencing Factors01:22

Bioavailability: Influencing Factors

Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.